Calamos Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Calamos Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41M	Buy	12,003 +3,468	+41%	+$348K	﹤0.01%	705
2026 Q1	$788K	Buy	+8,535	New	+$803K	﹤0.01%	827
2025 Q4	–	Sell	-43,250	Closed	-$3.17M	–	975
2025 Q3	$3.17M	Buy	43,250 +9,985	+30%	+$635K	0.01%	593
2025 Q2	$1.69M	Sell	33,265 -3,389	-9%	-$151K	0.01%	648
2025 Q1	$1.65M	Buy	+36,654	New	+$1.73M	0.01%	608
2022 Q4	–	Sell	-108,653	Closed	-$2.28M	–	1291
2022 Q3	$2.28M	Buy	108,653 +66,132	+156%	+$1.59M	0.01%	850
2022 Q2	$828K	Buy	+42,521	New	+$1M	﹤0.01%	1039

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Calamos Advisors's MIRM Position: Q2 2026 in Review

Calamos Advisors increased its Mirum Pharmaceuticals (MIRM) stake by 41% in Q2 2026, buying an estimated $348K and bringing the position to 12,003 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #705.

Calamos Advisors first reported a position in MIRM in Q2 2022 and has held it in 7 quarters since. The position peaked at $3.17M in Q3 2025. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Calamos Advisors held 12,003 shares of Mirum Pharmaceuticals worth $1.41M as of Q2 2026.
Calamos Advisors bought 3,468 Mirum Pharmaceuticals shares in Q2 2026, an estimated $348K.
Mirum Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #705 holding.
Calamos Advisors first reported a position in Mirum Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
Calamos Advisors's Mirum Pharmaceuticals position peaked at $3.17M in Q3 2025.
328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.